Radicle GI Health: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes.
NCT ID: NCT07212231
Last Updated: 2025-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1650 participants
INTERVENTIONAL
2025-10-16
2026-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radicle GI HealthTM RCA: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes
NCT07130058
Efficacy of Dietary Supplement in Subjects With Acid Reflux and/or Abdominal Bloating/Distention and GI Symptoms
NCT06808867
Effect of a Nutritional Supplement on Gut Microbiota in Adults
NCT06611215
Trial to Evaluate Dietary Supplements to Maintain Gut Health During Travel
NCT04605783
A Study Assessing the Impact of a Women's Health Formulation on Vaginal Health and the Microbial Community
NCT07036666
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Control
GI Product Placebo Control
GI Product Placebo Control
Participants will use their GI Product Placebo Control as directed for a period of 6 weeks.
Active Product 1
GI Active Product 1
Active Product 1
Participants will use their GI Active Product 1 as directed for a period of 6 weeks.
Active Product 2
GI Active Product 2
Active Product 2
Participants will use their GI Active Product 2 as directed for a period of 6 weeks.
Active Product 3
GI Active Product 3
Active Product 3
Participants will use their GI Active Product 3 as directed for a period of 6 weeks.
Active Product 4
GI Active Product 4
Active Product 4
Participants will use their GI Active Product 4 as directed for a period of 6 weeks.
Active Product 5
GI Active Product 5
Active Product 5
Participants will use their GI Active Product 5 as directed for a period of 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GI Product Placebo Control
Participants will use their GI Product Placebo Control as directed for a period of 6 weeks.
Active Product 1
Participants will use their GI Active Product 1 as directed for a period of 6 weeks.
Active Product 2
Participants will use their GI Active Product 2 as directed for a period of 6 weeks.
Active Product 3
Participants will use their GI Active Product 3 as directed for a period of 6 weeks.
Active Product 4
Participants will use their GI Active Product 4 as directed for a period of 6 weeks.
Active Product 5
Participants will use their GI Active Product 5 as directed for a period of 6 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Unable to provide a valid US shipping address and mobile phone number.
* Reports current enrollment in another clinical trial.
* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day).
* Unable to read and understand English.
* Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
* NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure.
* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
* Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products.
* Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk.
* Lack of reliable daily access to the internet.
21 Years
105 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Radicle Science
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susan Hewlings
Role: PRINCIPAL_INVESTIGATOR
Radicle Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radicle Science Inc.
Del Mar, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RADX_P_2407_RVS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.